Bank Of New York Mellon Corp Corvus Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$3.3 - $4.58 $121,822 - $169,075	-36,916 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$3.75 - $4.97 $686 - $909	-183 Reduced 0.49%	36,916 $149,000
Q4 2018 Feb 11, 2019	SELL	$3.29 - $8.94 $575 - $1,564	-175 Reduced 0.47%	37,099 $136,000
Q3 2018 Nov 09, 2018	BUY	$8.58 - $11.4 $1,501 - $1,995	175 Added 0.47%	37,274 $0
Q2 2018 Aug 06, 2018	BUY	$9.42 - $13.73 $92,146 - $134,306	9,782 Added 35.81%	37,099 $407,000
Q1 2018 May 15, 2018	SELL	$7.48 - $11.53 $3,425 - $5,280	-458 Reduced 1.65%	27,317 $315,000
Q4 2017 Feb 09, 2018	BUY	$9.3 - $16.93 $258,307 - $470,230	27,775	27,775 $288,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.